INNBC Project Gains Harvard Citation and Nears Steam Game Launch

Following 14,000+ activations of INNBC STARFIGHTER on Steam, the project is launching three new infrastructure products: - **INNBCswap**: A DeFi aggregator designed to compete with established platforms like 1inch and Kyber Network, using proprietary routing technology across major chains - **INNBC L1 Chain**: An EVM-compatible Layer-1 blockchain focused on decentralized science (DeSci) and gaming, claiming 65,000 transactions per second with $INNBC as the native gas token - **INNBC Wallet**: A multi-chain wallet with native support for the INNBC Chain and major blockchains The project positions itself as product-focused rather than speculative, building on its 2018 DeSci token origins. The Steam game serves as an entry point to introduce blockchain concepts to mainstream gamers. [INNBC STARFIGHTER on Steam](https://store.steampowered.com/app/3977960/INNBC_STARFIGHTER/)

Innovative Bioresearch has released the INNBC STARFIGHTER Engine on GitHub, demonstrating that JavaScript can power commercial-grade games. **Key Features:** - Built with JavaScript and Electron - Delivers 60+ FPS arcade gameplay - Full Steam API integration including achievements - Online multiplayer and lobby support - Gamepad compatibility - Performance-optimized asset caching The engine powers their Steam-released shoot 'em up game and represents a working example of JavaScript technology in commercial gaming. The code is source-available under a commercial license for developers and studios. [View on GitHub](https://github.com/InnovativeBioresearch/INNBC-STARFIGHTER)

**Gaming Press Recognition** INNBC STARFIGHTER received coverage from Spaziogames, being featured as one of the top free-to-play titles on Steam during the Easter holiday period. **Game Details** - 90s-inspired arcade shooter with modern high-resolution graphics - Supports 60+ FPS gameplay - Single-player campaign and online co-op for 2 players - Free-to-play model - Currently available on Steam **DeSci Integration** The game represents an attempt to bridge decentralized science (DeSci) concepts with mainstream gaming. The project aims to provide utility beyond token speculation through actual gaming products. Full coverage: [Spaziogames article](https://www.spaziogames.it/notizie/8-piccoli-giochi-gratis-su-steam-per-festeggiare-la-pasqua)

A Springer Nature publication on blockchain-based biomedical data storage has received its second significant academic citation. Following an earlier reference from Harvard University, the research is now cited in a new study titled "BirthChain: a blockchain platform for birth certificates" published in Frontiers in Blockchain. The citation positions the work as a technical reference for implementing decentralized science (DeSci) solutions on BNB Smart Chain and other EVM-compatible networks including Ethereum and Polygon. **Key points:** - Research cited by institutions including Harvard and University College London - Study serves as practical reference for blockchain engineering applications - Published in peer-reviewed journals with established academic standards - Focuses on permanent data storage using blockchain technology The citations demonstrate growing academic interest in blockchain applications for data management and infrastructure development across multiple networks.

A **2-month mouse study protocol** for peptide BPC-157 has been officially submitted to the lab for preclinical testing. **Key Study Parameters:** - High-dose chronic safety testing (200 ug/kg) - Functional performance measurements (grip strength, cytokines) - Duration: 2 months **Regulatory Significance:** This dataset will address **critical non-toxicity requirements** from regulatory agencies including AIFA and EMA, which are necessary prerequisites for advancing to human Phase I clinical trials. **Previous Results:** Earlier C. elegans experiments showed a **5.1% increase in lifespan** - marking the first time BPC-157 was tested on this model organism. The study represents a crucial step in building the regulatory bridge toward official approval for human trials of this regenerative medicine peptide.